Lutetium Lu-177 Dotatate

A radiolabeled somatostatin analog in which the octapeptide DOTA-Tyr3-octreotate carries the beta emitter lutetium-177 into somatostatin receptor-positive tumor cells, FDA approved since 2018 for gastroenteropancreatic neuroendocrine tumors.

Also referenced as: Lutathera, 177Lu-DOTATATE, 177Lu-oxodotreotide, Lutetium oxodotreotide, PNT2003, Bravnetsa, Bexlutry

Also appears in: Hormone

COA Public product evidence No certificate records are bound to a tracked Lutetium Lu-177 Dotatate product page A record counts here only when a vendor publishes a certificate against one of its own tracked Lutetium Lu-177 Dotatate product pages. Other certificates naming this compound may still exist — search the wider certificate database. →

---

What is Lutetium Lu-177 Dotatate?

Lutetium Lu-177 dotatate is a radiolabeled somatostatin analog: the cyclic octapeptide octreotate (octreotide with a C-terminal threonine in place of threoninol and a tyrosine at position 3) linked through the chelator DOTA to the radioactive metal lutetium-177. The peptide portion is a close relative of octreotide and lanreotide and binds the same somatostatin receptors; the lutetium-177 is what makes it a cancer treatment rather than a hormone-suppressing drug. Marketed as Lutathera by Advanced Accelerator Applications, a Novartis company, it is approved by the FDA for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It is also called 177Lu-oxodotreotide, the international nonproprietary name for the molecule. Two further lutetium Lu 177 dotatate products, Bexlutry (Curium) and Bravnetsa (Lantheus), are approved in the United States for the adult indication.

It is one of the clearest examples of a peptide used as a delivery vehicle: the entire therapeutic concept, peptide receptor radionuclide therapy (PRRT), rests on a peptide that tumor cells recognize and pull inside. It does not appear to have any presence in the research-peptide market, as expected for a short-lived radiopharmaceutical manufactured to order and handled only under radiation licenses.

How it works

The simplest way to read the molecule is as two parts with two jobs. The peptide is the address label; the radionuclide is the payload.

• The peptide finds the tumor. Well-differentiated neuroendocrine tumors overexpress somatostatin receptors, especially subtype 2 (SSTR2). DOTA-Tyr3-octreotate binds SSTR2 with low-nanomolar affinity, higher than the corresponding DOTA-octreotide and DOTA-lanreotide conjugates in side-by-side receptor assays, which is why octreotate rather than octreotide became the preferred therapeutic vector (Reubi et al., European Journal of Nuclear Medicine, 2000). After binding, the receptor-ligand complex is internalized, concentrating the radionuclide inside the tumor cell (FDA label, Clinical Pharmacology section).
• The beta particle does the damage. Lutetium-177 decays with a half-life of 6.647 days, emitting beta-minus particles with a maximum energy of 0.498 MeV. Those particles travel a mean of 0.67 mm and at most 2.2 mm in soft tissue, so the energy is deposited in the cell that took up the drug and its immediate neighbors, including adjacent tumor cells that may express fewer receptors, while sparing tissue farther away (FDA label, Description and Mechanism of Action sections). The DNA damage from that radiation, not any pharmacologic effect of the peptide, is what shrinks or stalls the tumor.
• The gamma photons allow imaging. Lutetium-177 also emits gamma photons at 208 keV and 113 keV, which can be detected by a gamma camera. Treatment uptake can therefore be imaged and absorbed doses to kidneys and bone marrow estimated from the same administration, which is how the pediatric dosimetry in NETTER-P was performed (Gaze et al., European Journal of Nuclear Medicine and Molecular Imaging, 2025).
• The same targeting carries the toxicity. Somatostatin receptors are also present on normal tissue, and the radioactive conjugate is cleared through the kidneys and circulates past the bone marrow. Hematologic toxicity and, rarely, renal or marrow injury follow directly from the biodistribution rather than from an off-target drug effect (Kwekkeboom et al., Journal of Clinical Oncology, 2008).

Octreotide and lanreotide, given unlabeled, occupy the same receptors, so the therapeutic analog and the radiolabeled one compete for the same binding sites.

Research status

Lutetium Lu-177 dotatate has a large evidence base for a peptide-based radiopharmaceutical, built on a large single-center experience followed by two randomized Phase 3 trials.

The Rotterdam cohort. Kwekkeboom et al. (Journal of Clinical Oncology, 2008, 26(13):2124-2130) reported toxicity in 504 patients and efficacy in 310 patients with GEP-NETs treated at Erasmus Medical Center. Complete and partial remissions occurred in 2% and 28% respectively, median time to progression was 40 months, and serious treatment-attributable events included myelodysplastic syndrome in three patients. These data (the “ERASMUS” study in the US label) supported the original approval alongside NETTER-1, and the label’s response-rate figure of 17% with a median duration of response of 35 months comes from a 360-patient GEP-NET efficacy subset of this experience.

NETTER-1 (NCT01578239). Strosberg et al. (New England Journal of Medicine, 2017, 376(2):125-135) randomized 229 patients with inoperable, progressive, somatostatin receptor-positive midgut neuroendocrine tumors to 177Lu-Dotatate plus standard-dose octreotide LAR versus high-dose octreotide LAR alone. At the primary analysis, median progression-free survival was not reached with 177Lu-Dotatate versus 8.4 months with high-dose octreotide (hazard ratio 0.21), and the objective response rate was 18% versus 3%. The prespecified final overall survival analysis (Strosberg et al., Lancet Oncology, 2021, 22(12):1752-1763) found a median of 48.0 months versus 36.3 months, a hazard ratio of 0.84 with a 95% confidence interval of 0.60 to 1.17 and p = 0.30. The overall survival endpoint was not met, a result the authors attributed in part to 36% of control patients crossing over to radioligand therapy after progression. No new safety signals emerged over a median follow-up of about 76 months. A separate analysis showed that health-related quality of life was maintained longer in the 177Lu-Dotatate arm (Strosberg et al., Journal of Clinical Oncology, 2018).

NETTER-2 (NCT03972488). Singh et al. (Lancet, 2024, 403(10446):2807-2817) moved the drug to first line in a harder population: 226 patients with newly diagnosed, advanced, well-differentiated grade 2 or grade 3 GEP-NETs (Ki-67 10% to 55%), randomized 2:1 to 177Lu-DOTATATE plus standard-dose octreotide LAR versus high-dose octreotide LAR alone. Median progression-free survival was 22.8 months versus 8.5 months (hazard ratio 0.276, p < 0.0001). Overall survival was immature at publication and no difference between arms had been observed. One case of myelodysplastic syndrome was reported in the 177Lu-DOTATATE arm. Preplanned and post hoc analyses published in 2026 reported consistent progression-free survival benefit across tumor grade and primary site (Ferone et al., eClinicalMedicine, 2026). NETTER-2 has not, as of November 2026, produced a change to the US indication, which already covers these tumors without a line-of-therapy restriction.

NETTER-P (NCT04711135). The pediatric extension rested on an open-label Phase 2 safety and dosimetry study in 11 adolescents aged 12 to 17 (four with GEP-NETs, seven with pheochromocytoma or paraganglioma). Projected kidney and marrow absorbed doses fell within adult thresholds, and lymphopenia was the most common adverse event (Gaze et al., European Journal of Nuclear Medicine and Molecular Imaging, 2025, 52(11):4001-4015). Efficacy in adolescents was extrapolated from NETTER-1, and the FDA imposed a long-term safety study in adolescents as a postmarketing requirement.

Regulatory record. The European Commission authorized Lutathera on September 26, 2017. The FDA approved it on January 26, 2018 for adults and extended the indication to patients 12 years and older on April 23, 2024. The US label has since been revised several times, most recently through a labeling supplement approved November 26, 2024; the current prescribing information carries an October 2024 revision date, and no new indication was approved in 2025 or 2026. Follow-on products arrived in 2026. On March 2, 2026, the FDA granted tentative approval to an abbreviated new drug application for a “radioequivalent” lutetium Lu 177 dotatate (PNT2003, Lantheus) pending the end of a Hatch-Waxman 30-month stay; final approval of that product, now named Bravnetsa, was announced September 22, 2026. Curium’s Bexlutry, approved through the 505(b)(2) pathway with Lutathera as the reference product, was announced September 14, 2026. Both follow-on labels carry the adult indication only; the adolescent indication remains exclusive to Lutathera.

Active work. ClinicalTrials.gov lists more than 60 open studies involving the compound as of November 2026. The sponsor’s NETTER-3 trial (NCT06784752, Phase 3, recruiting, estimated primary completion December 8, 2028) tests first-line use in newly diagnosed grade 1 and grade 2 (Ki-67 below 10%) advanced GEP-NETs with high disease burden. Academic and cooperative-group studies are exploring retreatment after progression, dosimetry-guided dosing, combinations with PARP inhibitors, capecitabine-temozolomide or radiosensitizers, and off-label tumor types such as meningioma, pheochromocytoma and paraganglioma, bronchial NETs, small-cell lung cancer and neuroendocrine prostate cancer. Competing somatostatin-receptor radioligands using the same peptide vector with alpha emitters (actinium-225) or different peptides (DOTATOC) are in separate development and are not the same drug.

Common dosage forms

• Lutathera. A sterile solution for intravenous infusion supplied in a single-dose 30 mL glass vial containing 7.4 GBq (200 mCi) of lutetium Lu 177 dotatate at a radioactive concentration of 370 MBq/mL (10 mCi/mL), in 20.5 to 25 mL of solution, delivered inside a lead-shielded container labeled with a calibration date and time.
• Follow-on products. Bexlutry and Bravnetsa are lutetium Lu 177 dotatate injections approved in September 2026 for the adult GEP-NET indication, Bexlutry under the 505(b)(2) pathway and Bravnetsa as the first radiopharmaceutical approved through an abbreviated new drug application.

Key considerations

• Regulatory status. The FDA Approved status reflects Lutathera, approved January 26, 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults and extended to patients 12 and older on April 23, 2024. Bexlutry and Bravnetsa followed in September 2026 for adults. All three are dispensed and administered under radiation-safety licensing.
• Progression versus survival. NETTER-1 showed a 79% reduction in the hazard of progression but did not meet its overall survival endpoint (hazard ratio 0.84, p = 0.30), and NETTER-2’s survival data were immature at publication. Crossover complicates the interpretation, but the result is that lutetium Lu-177 dotatate has been shown to delay progression and preserve quality of life, not yet to extend life in a randomized comparison.
• Hematologic and late-onset risks. In NETTER-1, anemia, thrombocytopenia and neutropenia of any grade affected 81%, 53% and 26% of treated patients. Secondary myelodysplastic syndrome occurred in about 2% of patients in both NETTER-1 and the label’s summary of the Rotterdam experience, and acute leukemia in 0.5% of the latter, typically appearing years after treatment. The label also warns of renal toxicity, neuroendocrine hormonal crises around the first infusion, and infertility at the cumulative dose used in the trials.
• Receptor competition. Because the therapeutic somatostatin analogs occupy the same receptors, high-dose octreotide LAR was the comparator in both Phase 3 trials rather than placebo. The relationship between the three peptides is competitive at the receptor, not additive.
• Naming. Lutathera, Bexlutry, Bravnetsa, 177Lu-DOTATATE, 177Lu-oxodotreotide and lutetium Lu 177 dotatate all describe the same drug; “DOTA-TATE” alone is the unlabeled peptide. 177Lu-DOTATOC (edotreotide), 177Lu-PSMA-617 (a prostate cancer radioligand with no somatostatin peptide) and gallium-68 DOTATATE imaging agents are different products that share part of the name, and results from one do not transfer to another.